Slingshot members are tracking this event:
OncoSec Medical (ONCS) Phase 2 Results Evaluating ImmunoPulse IL-12 and Merck's (MRK) Keytruda in Metastatic Melanoma
Slingshot Insights Explained
Feb 23, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 2, Immunopulse Il-12, Keytruda, Metastatic Melanoma, Pd-1 Inhibition